Abstract: The invention provides polypeptides that act both as an agonist of the GLP-1 receptor and an antagonist of the glucagon receptor. Such polypeptides are useful for treating individuals with type 2 diabetes or other metabolic disorders.
Type:
Grant
Filed:
October 3, 2002
Date of Patent:
March 8, 2005
Assignee:
Bayer Pharmaceuticals Corporation
Inventors:
Clark Pan, James Whelan, Kevin B. Clairmont
Abstract: Disclosed herein are novel genes and methods for the screening of therapeutics useful for treating impaired glucose tolerance conditions, as well as diagnostics and therapeutic compositions for identifying or treating such conditions.
Abstract: The present invention relates to isolated proteins or polypeptides of grapevine leafroll virus (type 2). The encoding DNA molecules either alone in isolated form or in an expression system, a host cell, or a transgenic grape plant are also disclosed. Other aspects of the present invention relates to a method of imparting grapevine leafroll resistance, to grape and tobacco plants by transforming them with the DNA molecules of the present invention, a method of imparting beet yellows virus resistance to a beet plant, a method of imparting tristeza virus resistance to a citrus plant, and a method of detecting the presence of a grapevine leafroll virus, such as GRLaV-2, in a sample.
Type:
Grant
Filed:
July 11, 2000
Date of Patent:
February 22, 2005
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Hai-Ying Zhu, Kai-Shu Ling, Dennis Gonsalves
Abstract: The invention concerns single-chain antibodies directed against the p53 protein, capable of being expressed in tumoral cells, capable of restoring a DNA binding in vitro and a transcription activator function in vivo. The invention also concerns nucleic acids coding for these molecules, the vectors containing them and their uses.
Type:
Grant
Filed:
October 27, 1997
Date of Patent:
February 8, 2005
Inventors:
Laurent Bracco, Laurent Debussche, Claude Caron De Fromentel
Abstract: isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1(omi1), BRCA1(omi2), and BRCA1(omi3) and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.
Type:
Grant
Filed:
December 13, 2000
Date of Patent:
January 4, 2005
Assignee:
Gene Logic Inc.
Inventors:
Patricia D. Murphy, Antonette C. Allen, Christopher P. Alvares, Brenda S. Critz, Sheri J. Olson, Denise B. Schelter, Bin Zeng
Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Type:
Grant
Filed:
January 27, 2000
Date of Patent:
December 21, 2004
Assignees:
Institut Pasteur, Universite Pierre et Marie Curie
Inventors:
Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
Abstract: The invention provides Drosophila melanogaster p70S6K, as well as nucleic acids encoding this kinase. The sequence of Drosophila p70S6K and the gene encoding it are represented in SEQ ID No. 2 and 1 respectively. The invention moreover provides mutated forms of Drosophila p70S6K, including constitutively active and dominant negative forms thereof, which are useful in the study of p70S6K activity. Furthermore, the invention provides expression systems which produce Drosophila p70S6K in Drosophila and other organisms, and in particular systems in which expression of Drosophila p70S6K has been modulated so as to facilitate the study of its activity.
Type:
Grant
Filed:
January 31, 2003
Date of Patent:
December 21, 2004
Assignee:
Novartis, AG
Inventors:
Mary Stewart, Sara Kozma, George Thomas
Abstract: The invention relates to mammalian cell lines and transgenic mammals. More particularly, it relates to a method for producing a rat cell line, a method for producing a transgenic rat, a transgenic rat, a rat cell line, cells and tissue obtained therefrom and uses therefore. The cell line derived from a transgenic mammal comprises: (i) a conditional oncogene, transforming gene or immortalising gene or a cell cycle affecting gene; and (ii) a cell type specific promoter. They include a neuronal cell line in which the cell type specific promoter is an NF-L gene promoter, and a mammary cell line in which the cell type specific promoter is a MMTV gene promoter. The conditional oncogene, transforming gene or immortalising gene is preferably a SV40tsA58 gene.
Type:
Grant
Filed:
October 16, 1998
Date of Patent:
November 30, 2004
Inventors:
Philip Spencer Rudland, Barry Roger Barraclough, Iain Charles Kilty, Barry Robert Davies, Guenter Schmidt
Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
Type:
Grant
Filed:
February 4, 1999
Date of Patent:
November 23, 2004
Assignees:
Institut Pasteur, Universite Pierre et Marie Curie
Inventors:
Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
Abstract: The present invention relates to a plasmid carrying simian immunodeficiency virus (SIV)-derived genes. Particularly, the present invention relates to the plasmid pSIV/GE which carrys gag, protease, env and rev gene, all derived from SIV, but not tat and nef gene and the plasmid pSIV/pol which carrys SIV-derived pol gene; the plasmid pHIV/GE and pHIV/pol that are substituted the SIV-derived genes in the plasmid pSIV/GE and pSIV/pol by human immunodeficiency virus (HIV)-derived corresponding genes; DNA vaccine containing the plasmid pSIV/GE and pSIV/pol; and DNA vaccine containing the plasmid pHIV/GE and pHIV/pol. The present invention offers AIDS DNA vaccines which successfully exert perfect medicinal efficacy on primates, giving a measure of success in developing effective AIDS DNA vaccines applicable to humans. The plasmid of the present invention can be effectively used for not only AIDS prevention by AIDS infection but also therapeutic agent for AIDS.
Type:
Grant
Filed:
December 6, 2000
Date of Patent:
November 16, 2004
Assignees:
Genexine Co. Ltd., Pohang University of Science and Technology
Abstract: The present invention relates to polynucleotides associated with angiogenesis-related disorders. The present invention also relates to canine endostatin genes, novel genes associated with angiogenesis-related disorders, such as cancer. The invention encompasses endostatin nucleic acids, recombinant DNA molecules, cloned genes or degenerate variants thereof, endostatin gene products and antibodies directed against such gene products, cloning vectors containing mammalian endostatin gene molecules, and hosts that have been genetically engineered to express such molecules. The invention further relates to methods for the identification of compounds that modulate the expression of endostatin genes and gene products and to using such compounds as therapeutic agents in the treatment of angiogenesis-related disorders, e.g., cancer. The invention also relates to methods for the diagnostic evaluation, genetic testing and prognosis of angiogenesis-related disorders, e.g.
Abstract: The present invention is broadly directed to therapeutic molecules capable of inter alia modulating apoptosis in mammalian cells. The therapeutic molecules of the present invention encompass genetic sequences and chemical entities capable of regulating expression of a novel mammalian gene belonging to the bcl-2 family and which promotes cell survival. The therapeutic molecules of the present invention may have further utility in delaying cell cycle entry. In addition, the present invention extends to chemical entities capable of modulating activity and function of the translation product of said novel gene of the bcl-2 family. The present invention also extends to the translation product of the novel gene of the bcl-2 family and its use in, for example, therapy, diagnosis, antibody generation and as a screening tool for therapeutic molecules capable of modulating physiological cell death or survival and/or modulating cell cycle entry.
Type:
Grant
Filed:
March 29, 1999
Date of Patent:
September 14, 2004
Assignee:
Cerylid Pty., Ltd.
Inventors:
Suzanne Cory, Jerry McKee Adams, Leonie M. Gibson, Shaun P. Holmgreen
Abstract: The present invention relates to methods and materials used to isolate and detect a high bone mass gene and a corresponding wild-type gene, and mutants thereof. The present invention also relates to the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The genes identified in the present invention are implicated in bone development. The invention also provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.
Type:
Grant
Filed:
April 5, 2000
Date of Patent:
August 24, 2004
Assignee:
Genome Therapeutics Corporation
Inventors:
John P. Carulli, Randall D. Little, Robert R. Recker, Mark L. Johnson
Abstract: This invention provides for murine telomerase reverse transcriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.
Type:
Grant
Filed:
March 16, 1998
Date of Patent:
July 27, 2004
Assignees:
Geron Corporation, Albert Einstein College of Medicine of Yeshiva University, a
division of Yeshiva University
Inventors:
Gregg B. Morin, Richard Allsopp, Ronald A. DePinho, Roger A. Greenberg
Abstract: In accordance with the present invention, there are provided various methods for modulating the expression of an exogenous gene in a mammalian subject employing modified ecdysone receptors. Also provided are modified ecdysone receptors, as well as homomeric and heterodimeric receptors containing same, nucleic acids encoding invention modified ecdysone receptors, modified ecdysone response elements, gene transfer vectors, recombinant cells, and transgenic animals containing nucleic acids encoding invention modified ecdysone receptor.
Type:
Grant
Filed:
March 16, 1998
Date of Patent:
April 20, 2004
Assignee:
The Salk Institute for Biological Studies
Inventors:
Ronald M. Evans, David No, Enrique Saez
Abstract: Genes coding for vascular cell adhesion molecules, particularly VCAM-1, are modulated through interaction of oligonucleotides with transcriptional regulatory factors which bind to the genes. Specific and effective oligonucleotides are provided which interact with the transcriptional regulatory factors to diminish their interaction with the genes and downregulate their function. Multi-modal oligonucleotides are also provided which interact both with a transcriptional regulatory factor and with another aspect of gene function.
Type:
Grant
Filed:
March 9, 1995
Date of Patent:
March 30, 2004
Assignees:
ISIS Pharmaceuticals, Inc., Emory University
Inventors:
Russell M. Medford, Clarence Frank Bennett
Abstract: The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention.
Type:
Grant
Filed:
February 27, 1998
Date of Patent:
March 30, 2004
Assignees:
University of Utah Research Foundation, Baylor College of Medicine, Johns Hopkins University, The United States of America as represented by the Department
of Health and Human Services
Inventors:
Rando Allikmets, Kent L. Anderson, Michael Dean, Mark Leppert, Richard A. Lewis, Yixin Li, James R. Lupski, Jeremy Nathans, Amir Rattner, Noah F. Shroyer, Nanda Singh, Philip Smallwood, Hui Sun
Abstract: The invention relates to an animal model of cancer. The animal carries a tumour xenograft and is immunosuppressed by administration of cyclosporin and ketoconazole. The model is useful for studying cancer and treatment thereof.
Abstract: Disclosed is substantially pure DNA encoding mammalian IAP polypeptides; substantially pure polypeptides; and methods of using such DNA to express the IAP polypeptides in cells and animals to inhibit apoptosis. Also disclosed are conserved regions characteristic of the IAP family and primers and probes for the identification and isolation of additional IAP genes. In addition, methods for treating diseases and disorders involving apoptosis are provided.
Type:
Grant
Filed:
December 1, 1998
Date of Patent:
February 10, 2004
Assignee:
AEGERA Therapeutics Inc.
Inventors:
Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston